Laboratory validation of a clinical metagenomic next-generation sequencing assay for respiratory virus detection and discovery
Jessica Karielle Tan,Venice Servellita,Doug Stryke,Emily Kelly,Jessica Streithorst,Nanami Sumimoto,Abiodun Foresythe,Hee Jae Huh,Jenny Nguyen,Miriam Oseguera,Noah Brazer,Jack Tang,Danielle Ingebrigtsen,Becky Fung,Helen Reyes,Melissa Hillberg,Alice Chen,Hugo Guevara,Shigeo Yagi,Christina Morales,Debra A. Wadford,Peter M. Mourani,Charles R. Langelier,Mikael de Lorenzi-Tognon,Patrick Benoit,Charles Y. Chiu
DOI: https://doi.org/10.1101/2024.02.28.24303521
2024-03-22
Abstract:Tools for rapid identification of novel and/or emerging viruses are urgently needed for clinical diagnosis of unexplained infections and pandemic preparedness. Here we developed and clinically validated a largely automated metagenomic next-generation sequencing (mNGS) assay for agnostic detection of respiratory viral pathogens from nasopharyngeal swab, bronchoalveolar lavage and tracheal aspirate samples in <24 hours. The mNGS assay achieved mean limits of detection of 543 copies/mL, viral load quantification with 100% linearity, and 93.6% sensitivity, 93.8% specificity, and 93.7% accuracy compared to gold-standard clinical multiplex RT-PCR. Performance increased to 97.9% overall predictive agreement after discrepancy testing and clinical adjudication, which was superior to that of RT-PCR (95.0% agreement). To enable discovery of novel, sequence-divergent human viruses with pandemic potential, assembly and translated nucleotide algorithms were incorporated into the automated SURPI+ computational pipeline used by the mNGS assay for pathogen detection. Using analysis, we showed after removal of all human viral sequences from the reference database that 70 (100%) of 70 representative human viral pathogens could still be identified based on homology to related animal or plant viruses. Our assay, which was granted breakthrough device designation from the US Food and Drug Administration (FDA) in August of 2023, demonstrates the feasibility of routine mNGS testing in clinical and public health laboratories, thus enabling a robust and rapid response to the next viral respiratory pandemic.
Infectious Diseases (except HIV/AIDS)